CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,047 | +64.9% | 35,217 | 0.0% | 0.01% | +83.3% |
| Q2 2023 | $635 | -18.3% | 35,217 | -27.2% | 0.01% | -25.0% |
| Q1 2023 | $777 | -5.6% | 48,355 | +7.5% | 0.01% | -11.1% |
| Q4 2022 | $823 | -99.9% | 44,989 | 0.0% | 0.01% | -10.0% |
| Q3 2022 | $884,000 | +45.9% | 44,989 | +63.0% | 0.01% | +66.7% |
| Q1 2022 | $606,000 | -22.7% | 27,597 | 0.0% | 0.01% | -14.3% |
| Q4 2021 | $784,000 | +34.9% | 27,597 | 0.0% | 0.01% | +40.0% |
| Q3 2021 | $581,000 | – | 27,597 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |